Olfactory heterogeneity in LRRK2 related Parkinsonism

LRRK2 mutations can cause familial and sporadic Parkinson's disease (PD) with Lewy‐body pathology at post‐mortem. Studies of olfaction in LRRK2 are sparse and incongruent. We applied a previously validated translation of the 16 item smell identification test from Sniffin' Sticks (SS‐16) to 14 parkinsonian carriers of heterozygous G2019S LRRK2 mutation and compared with 106 PD patients and 118 healthy controls. The mean SS‐16 score in LRRK2 was higher than in PD (p < 0.001, 95% CI for β = −4.7 to −1.7) and lower than in controls (p = 0.007, 95% CI for β = +0.6 to +3.6). In the LRRK2 group, subjects with low scores had significantly more dyskinesia. They also had younger age of onset, longer disease duration, and reported less frequently a family history of PD, but none of these other differences reached significance. Odor identification is diminished in LRRK2 parkinsonism but not to the same extent as in idiopathic PD. © 2010 Movement Disorder Society

[1]  Brian Spencer,et al.  Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein , 2009, Proceedings of the National Academy of Sciences.

[2]  David R Williams,et al.  The use of a color coded probability scale to interpret smell tests in suspected parkinsonism , 2009, Movement disorders : official journal of the Movement Disorder Society.

[3]  Y. Agid,et al.  A clinical, neuropsychological and olfactory evaluation of a large family with LRRK2 mutations. , 2009, Parkinsonism & related disorders.

[4]  Z. Wszolek,et al.  Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes. , 2009, Parkinsonism & related disorders.

[5]  A. Petrie,et al.  Regional differences in the severity of Lewy body pathology across the olfactory cortex , 2009, Neuroscience Letters.

[6]  E. Waxman,et al.  Clinical and pathological characteristics of patients with Leucine‐rich repeat kinase‐2 mutations , 2009, Movement disorders : official journal of the Movement Disorder Society.

[7]  J. Holton,et al.  Hyposmia in G2019S LRRK2-related parkinsonism , 2008, Neurology.

[8]  A. Felício,et al.  Genetic and environmental findings in early‐onset Parkinson's disease Brazilian patients , 2008, Movement disorders : official journal of the Movement Disorder Society.

[9]  E. Tolosa,et al.  Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study , 2008, The Lancet Neurology.

[10]  M. Farrer,et al.  LRRK2 mutation in familial Parkinson's disease in a Taiwanese population: clinical, PET, and functional studies. , 2008, Journal of biomedical science.

[11]  H. Braak,et al.  Invited Article: Nervous system pathology in sporadic Parkinson disease , 2008, Neurology.

[12]  R. Hauser,et al.  Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease , 2008, Nature Medicine.

[13]  Elisabet Englund,et al.  Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation , 2008, Nature Medicine.

[14]  A. Lang,et al.  The G2019S LRRK2 mutation in Brazilian patients with Parkinson's disease: Phenotype in monozygotic twins , 2008, Movement disorders : official journal of the Movement Disorder Society.

[15]  H. Braak,et al.  Parkinson's disease: a dual‐hit hypothesis , 2007, Neuropathology and applied neurobiology.

[16]  E. Tolosa,et al.  G2019S LRRK2 mutation causing Parkinson’s disease without Lewy bodies , 2007, Journal of Neurology, Neurosurgery & Psychiatry.

[17]  M. Farrer,et al.  Lrrk2 G2019S substitution in frontotemporal lobar degeneration with ubiquitin-immunoreactive neuronal inclusions , 2007, Acta Neuropathologica.

[18]  M. Farrer,et al.  Parkinsonism, Lrrk2 G2019S, and tau neuropathology , 2006, Neurology.

[19]  Irene Litvan,et al.  Lrrk2 and Lewy body disease , 2006, Annals of neurology.

[20]  J. Trojanowski,et al.  Biochemical and pathological characterization of Lrrk2 , 2006, Annals of neurology.

[21]  A. Singleton,et al.  Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. , 2005, Brain : a journal of neurology.

[22]  T. Nägele,et al.  Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease*. , 2005, Brain : a journal of neurology.

[23]  Vincenzo Bonifati,et al.  A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease , 2005, The Lancet.

[24]  Thomas Meitinger,et al.  Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology , 2004, Neuron.

[25]  V. Fung,et al.  Identifying the pattern of olfactory deficits in Parkinson disease using the brief smell identification test. , 2003, Archives of neurology.

[26]  C. Hawkes,et al.  Olfactory Evoked Responses and Identification Tests in Neurological Disease , 1998, Annals of the New York Academy of Sciences.

[27]  A. Lang,et al.  Olfactory dysfunction in familial parkinsonism , 1997, Neurology.

[28]  T. Hummel,et al.  Chemosensory event-related potentials in response to trigeminal and olfactory stimulation in idiopathic Parkinson's disease , 1997, Neurology.

[29]  R. Doty,et al.  A study of the test-retest reliability of ten olfactory tests. , 1995, Chemical senses.

[30]  S. Daniel,et al.  The anterior olfactory nucleus in Parkinson's disease , 1995, Movement disorders : official journal of the Movement Disorder Society.

[31]  I. Kryspin-Exner,et al.  Impaired olfactory function in Parkinson's disease , 1995, The Lancet.

[32]  C Adler,et al.  Olfactory function in Parkinson's disease subtypes , 1994, Neurology.

[33]  R. Doty,et al.  Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson's disease. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[34]  R. Doty,et al.  Olfactory dysfunction in parkinsonism , 1988, Neurology.